The Children's Hospital and Dana-Farber Cancer Institute proposes to participate as a member of the Pediatric Oncology Group (POG) in the scientific design and execution of cooperative and multi-disciplinary clinical research studies of childhood cancer. The objectives of this program are: 1. To imptove patient care and overall survival for children with cancer through participation in cooperative clinical research studies in the Pediatric Oncology Group. 2. Examine the biology of neoplasia in childhood solid tumors and leukemias through continued efforts in our own laboratories and in conjunction with the Tumor Biology Committee of POG. 3. Evaluate new approaches to cancer therapy in such areas as new agent development and supportive care. During the past several decades The Children's Hospital and Dana-Farber Cancer Institute have demonstrated a fine record of scientific contributions to the field of Pediatric Hematology and Oncology. The need for collaborative, multi-disciplinary protocols has been increasingly apparent to us over the past few years. We participated in the POG osteosarcoma study as a co-principal investigator and have established a childhood acute leukemia consortium. We wish to expand our collaborative efforts within the confines of the Pediatric Oncology Group.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA041573-01A1
Application #
3558395
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1986-09-30
Project End
1990-12-31
Budget Start
1986-09-30
Budget End
1986-12-31
Support Year
1
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02115
Ravindranath, Y; Chang, M; Steuber, C P et al. (2005) Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 19:2101-16
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Goorin, Allen M; Schwartzentruber, Douglas J; Devidas, Meenakshi et al. (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21:1574-80
Goorin, Allen M; Harris, Michael B; Bernstein, Mark et al. (2002) Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 20:426-33
Lacayo, N J; Lum, B L; Becton, D L et al. (2002) Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia. Leukemia 16:920-7
Berg, S L; Blaney, S M; Sullivan, J et al. (2000) Phase II trial of pyrazoloacridine in children with solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 22:506-9
Mahoney Jr, D H; Cohen, M E; Friedman, H S et al. (2000) Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study. Neuro Oncol 2:213-20
Parsons, S K; Mayer, D K; Alexander, S W et al. (2000) Growth factor practice patterns among pediatric oncologists: results of a 1998 Pediatric Oncology Group Survey. Economic Evaluation Working Group the Pediatric Oncology Group. J Pediatr Hematol Oncol 22:227-41
Thomas, P R; Deutsch, M; Kepner, J L et al. (2000) Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 18:3004-11
Cushing, B; Giller, R; Ablin, A et al. (1999) Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the pediatric oncology group and the children's cancer group. Am J Obstet Gynecol 181:353-8

Showing the most recent 10 out of 21 publications